Late Tuesday, an advisory panel of the Food & Drug Administration (FDA) voiced its approval for pirfenidone, the experimental lung drug from InterMune (ITMN). The panel voted 9-3 in favor of recommending pirfenidone to patients with idiopathic pulmonary fibrosis.
The FDA is expected to follow the advice of the advisory panel, although it's not required to do so. The regulatory agency is due to issue its final ruling on the drug's fate by early May.
What Happened When Alex Kenjeev Paid His Student Loan in Cash
Preserve Your Budget by Freezing Foods -- Savings Experiment

